Inspire Medical adds AtriCure CEO Michael Carrel to board

Filed July 24, 2026 · Period ending July 20, 2026 · ~1 min read

Key Changes

• medium

  Michael H. Carrel, President and CEO of AtriCure (a medical device company focused on atrial fibrillation treatments), appointed as Class III director effective July 20, 2026, with term through 2027 annual meeting.

  Item 5.02 verify on EDGAR →
• low

  Carrel assigned to Organization and Compensation Committee and Quality, Product Supply and Technology Committee.

  Item 5.02 verify on EDGAR →
• low

  Compensation follows standard non-employee director policy: $70,000 annual cash retainer, $300,000 initial equity grant vesting over three years, and $200,000 annual equity grants vesting after one year.

  Item 5.02 verify on EDGAR →